Title | Clinicopathologic and Molecular Features of Pancreatic Ductal Adenocarcinomas Harboring Alterations in COMPASS-like Complex Genes. |
Publication Type | Journal Article |
Year of Publication | 2023 |
Authors | Hissong E, Zhao L, Shi J |
Journal | Arch Pathol Lab Med |
Volume | 147 |
Issue | 9 |
Pagination | 1050-1059 |
Date Published | 2023 Sep 01 |
ISSN | 1543-2165 |
Keywords | Adenocarcinoma, Carcinoma, Pancreatic Ductal, Carcinoma, Squamous Cell, Epigenesis, Genetic, Humans, Mutation, Pancreatic Neoplasms |
Abstract | CONTEXT.—: Recent genome-wide sequencing studies have identified a subset of pancreatic ductal adenocarcinomas (PDACs) harboring significant alterations in epigenetic regulation genes, including the COMPASS-like complex genes. Whether this subset of PDACs has specific histologic characteristics or carries prognostic or therapeutic implications is unknown. OBJECTIVE.—: To determine the specific clinicopathologic and molecular features of PDACs carrying mutations in COMPASS-like complex genes. DESIGN.—: We analyzed a series of 103 primary and metastatic PDACs with comprehensive molecular profiling, including 13 PDACs carrying loss-of-function COMPASS-like complex gene alterations (study cohort). Another 45 patients carrying PDACs with wild-type COMPASS-like complex genes were used as the control group. RESULTS.—: PDACs within the study cohort were smaller, harboring frequent areas of poor differentiation and concurrent alterations in KRAS, TP53, SMAD4, and CDKN2A. A subset of metastatic PDACs from the study cohort showed squamous differentiation. There was a trend toward decreased survival in the study group. We further interrogated 2 public data sets and found that PDACs with COMPASS-like complex gene alterations have increased rates of TP53 mutation, body-tail location, poor differentiation or undifferentiated histology, and a higher death rate. CONCLUSIONS.—: COMPASS-like complex gene alterations likely represent a subset of more aggressive PDACs with poor or squamous differentiation histologically and increased concurrent TP53 mutations. These findings may have potential prognostic and therapeutic implications. |
DOI | 10.5858/arpa.2022-0103-OA |
Alternate Journal | Arch Pathol Lab Med |
PubMed ID | 36508685 |
PubMed Central ID | PMC10261500 |
Grant List | K08 CA234222 / CA / NCI NIH HHS / United States R37 CA262209 / CA / NCI NIH HHS / United States |
Related Faculty:
Erika Hissong, M.D.